Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Powell

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Ebiomedicine|January 1, 2025
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota researchNicola J Wyatt, Hannah Watson, Gregory R Young, et al.
Gut|June 10, 2020
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panelShahida Din, Alexandra Kent, Richard C Pollok, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
High-resolution promoter interaction analysis implicates genes involved in the activation of Type 3 Innate Lymphoid Cells in autoimmune disease riskValeriya Malysheva, Helen Ray-Jones, Nora Lakes, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Nature Immunology|August 10, 2023
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targetsJing Hua Zhao, David Stacey, Niclas Eriksson, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Ebiomedicine|January 1, 2025
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota researchNicola J Wyatt, Hannah Watson, Gregory R Young, et al.
Gut|June 10, 2020
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panelShahida Din, Alexandra Kent, Richard C Pollok, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
High-resolution promoter interaction analysis implicates genes involved in the activation of Type 3 Innate Lymphoid Cells in autoimmune disease riskValeriya Malysheva, Helen Ray-Jones, Nora Lakes, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Nature Immunology|August 10, 2023
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targetsJing Hua Zhao, David Stacey, Niclas Eriksson, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 9